,address1,address2,city,state,zip,country,phone,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,auditRisk,boardRisk,compensationRisk,shareHolderRightsRisk,overallRisk,governanceEpochDate,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,pegRatio,enterpriseToRevenue,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationMean,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,debtToEquity,revenuePerShare,returnOnAssets,returnOnEquity,grossProfits,freeCashflow,operatingCashflow,revenueGrowth,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,6310 Nancy Ridge Drive,Suite 101,San Diego,CA,92121,United States,858 752 6170,https://www.cidara.com,Biotechnology,Healthcare,"Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.",73,"{'maxAge': 1, 'name': 'Dr. Jeffrey L. Stein Ph.D.', 'age': 67, 'title': 'Pres, CEO & Exec. Director', 'yearBorn': 1955, 'fiscalYear': 2022, 'totalPay': 873250, 'exercisedValue': 0, 'unexercisedValue': 0}",8,6,8,8,8,1693526400,1672444800,86400,4,1.09,1.08,1.05,1.1092,1.09,1.08,1.05,1.1092,0.0,1.26798,-2.0188682,471224,471224,626772,1166230,1166230,1.07,1.09,1100,1300,96569320,0.46,2.1,1.1419268,0.96746,1.127575,0.0,0.0,USD,50682368,-0.08924,75095770,90251696,1186790,1554275,1690761600,1693440000,0.013099999,0.09252,0.33742002,2.62,0.013300001,0.171,6.25731,1672444800,1703980800,1688083200,-7547000,-0.08,-0.53,-0.05,0.599,-6.276,NCM,EQUITY,CDTX,CDTX,"Cidara Therapeutics, Inc.","Cidara Therapeutics, Inc.",1429104600,America/New_York,EDT,-14400000,1.07,7.0,3.0,5.6,6.0,1.7,buy,5,50430000,0.559,-8075000,4543000,1.78,1.981,84567000,29.473,1.088,-0.095319994,-2.02522,-11232000,-422750,-1105000,0.225,0.10191,-0.09549,-0.09694,USD,
1,6310 Nancy Ridge Drive,Suite 101,San Diego,CA,92121,United States,858 752 6170,https://www.cidara.com,Biotechnology,Healthcare,"Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.",73,"{'maxAge': 1, 'name': 'Dr. Preetam  Shah M.B.A., Ph.D.', 'age': 49, 'title': 'CFO, Chief Bus. Officer & Principal Accounting Officer', 'yearBorn': 1973, 'fiscalYear': 2022, 'totalPay': 577850, 'exercisedValue': 0, 'unexercisedValue': 0}",8,6,8,8,8,1693526400,1672444800,86400,4,1.09,1.08,1.05,1.1092,1.09,1.08,1.05,1.1092,0.0,1.26798,-2.0188682,471224,471224,626772,1166230,1166230,1.07,1.09,1100,1300,96569320,0.46,2.1,1.1419268,0.96746,1.127575,0.0,0.0,USD,50682368,-0.08924,75095770,90251696,1186790,1554275,1690761600,1693440000,0.013099999,0.09252,0.33742002,2.62,0.013300001,0.171,6.25731,1672444800,1703980800,1688083200,-7547000,-0.08,-0.53,-0.05,0.599,-6.276,NCM,EQUITY,CDTX,CDTX,"Cidara Therapeutics, Inc.","Cidara Therapeutics, Inc.",1429104600,America/New_York,EDT,-14400000,1.07,7.0,3.0,5.6,6.0,1.7,buy,5,50430000,0.559,-8075000,4543000,1.78,1.981,84567000,29.473,1.088,-0.095319994,-2.02522,-11232000,-422750,-1105000,0.225,0.10191,-0.09549,-0.09694,USD,
2,6310 Nancy Ridge Drive,Suite 101,San Diego,CA,92121,United States,858 752 6170,https://www.cidara.com,Biotechnology,Healthcare,"Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.",73,"{'maxAge': 1, 'name': 'Dr. Taylor  Sandison', 'age': 50, 'title': 'Chief Medical Officer', 'yearBorn': 1972, 'fiscalYear': 2022, 'totalPay': 632050, 'exercisedValue': 0, 'unexercisedValue': 0}",8,6,8,8,8,1693526400,1672444800,86400,4,1.09,1.08,1.05,1.1092,1.09,1.08,1.05,1.1092,0.0,1.26798,-2.0188682,471224,471224,626772,1166230,1166230,1.07,1.09,1100,1300,96569320,0.46,2.1,1.1419268,0.96746,1.127575,0.0,0.0,USD,50682368,-0.08924,75095770,90251696,1186790,1554275,1690761600,1693440000,0.013099999,0.09252,0.33742002,2.62,0.013300001,0.171,6.25731,1672444800,1703980800,1688083200,-7547000,-0.08,-0.53,-0.05,0.599,-6.276,NCM,EQUITY,CDTX,CDTX,"Cidara Therapeutics, Inc.","Cidara Therapeutics, Inc.",1429104600,America/New_York,EDT,-14400000,1.07,7.0,3.0,5.6,6.0,1.7,buy,5,50430000,0.559,-8075000,4543000,1.78,1.981,84567000,29.473,1.088,-0.095319994,-2.02522,-11232000,-422750,-1105000,0.225,0.10191,-0.09549,-0.09694,USD,
3,6310 Nancy Ridge Drive,Suite 101,San Diego,CA,92121,United States,858 752 6170,https://www.cidara.com,Biotechnology,Healthcare,"Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.",73,"{'maxAge': 1, 'name': 'Dr. Kevin M. Forrest Ph.D.', 'age': 45, 'title': 'Founder and Chief Strategy Officer', 'yearBorn': 1977, 'fiscalYear': 2015, 'exercisedValue': 0, 'unexercisedValue': 0}",8,6,8,8,8,1693526400,1672444800,86400,4,1.09,1.08,1.05,1.1092,1.09,1.08,1.05,1.1092,0.0,1.26798,-2.0188682,471224,471224,626772,1166230,1166230,1.07,1.09,1100,1300,96569320,0.46,2.1,1.1419268,0.96746,1.127575,0.0,0.0,USD,50682368,-0.08924,75095770,90251696,1186790,1554275,1690761600,1693440000,0.013099999,0.09252,0.33742002,2.62,0.013300001,0.171,6.25731,1672444800,1703980800,1688083200,-7547000,-0.08,-0.53,-0.05,0.599,-6.276,NCM,EQUITY,CDTX,CDTX,"Cidara Therapeutics, Inc.","Cidara Therapeutics, Inc.",1429104600,America/New_York,EDT,-14400000,1.07,7.0,3.0,5.6,6.0,1.7,buy,5,50430000,0.559,-8075000,4543000,1.78,1.981,84567000,29.473,1.088,-0.095319994,-2.02522,-11232000,-422750,-1105000,0.225,0.10191,-0.09549,-0.09694,USD,
4,6310 Nancy Ridge Drive,Suite 101,San Diego,CA,92121,United States,858 752 6170,https://www.cidara.com,Biotechnology,Healthcare,"Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.",73,"{'maxAge': 1, 'name': 'Mr. Shane M. Ward', 'age': 47, 'title': 'COO & Chief Legal Officer', 'yearBorn': 1975, 'exercisedValue': 0, 'unexercisedValue': 0}",8,6,8,8,8,1693526400,1672444800,86400,4,1.09,1.08,1.05,1.1092,1.09,1.08,1.05,1.1092,0.0,1.26798,-2.0188682,471224,471224,626772,1166230,1166230,1.07,1.09,1100,1300,96569320,0.46,2.1,1.1419268,0.96746,1.127575,0.0,0.0,USD,50682368,-0.08924,75095770,90251696,1186790,1554275,1690761600,1693440000,0.013099999,0.09252,0.33742002,2.62,0.013300001,0.171,6.25731,1672444800,1703980800,1688083200,-7547000,-0.08,-0.53,-0.05,0.599,-6.276,NCM,EQUITY,CDTX,CDTX,"Cidara Therapeutics, Inc.","Cidara Therapeutics, Inc.",1429104600,America/New_York,EDT,-14400000,1.07,7.0,3.0,5.6,6.0,1.7,buy,5,50430000,0.559,-8075000,4543000,1.78,1.981,84567000,29.473,1.088,-0.095319994,-2.02522,-11232000,-422750,-1105000,0.225,0.10191,-0.09549,-0.09694,USD,
5,6310 Nancy Ridge Drive,Suite 101,San Diego,CA,92121,United States,858 752 6170,https://www.cidara.com,Biotechnology,Healthcare,"Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.",73,"{'maxAge': 1, 'name': 'Ms. Allison  Lewis CCP, SPHR', 'title': 'Sr. VP of People & Culture', 'exercisedValue': 0, 'unexercisedValue': 0}",8,6,8,8,8,1693526400,1672444800,86400,4,1.09,1.08,1.05,1.1092,1.09,1.08,1.05,1.1092,0.0,1.26798,-2.0188682,471224,471224,626772,1166230,1166230,1.07,1.09,1100,1300,96569320,0.46,2.1,1.1419268,0.96746,1.127575,0.0,0.0,USD,50682368,-0.08924,75095770,90251696,1186790,1554275,1690761600,1693440000,0.013099999,0.09252,0.33742002,2.62,0.013300001,0.171,6.25731,1672444800,1703980800,1688083200,-7547000,-0.08,-0.53,-0.05,0.599,-6.276,NCM,EQUITY,CDTX,CDTX,"Cidara Therapeutics, Inc.","Cidara Therapeutics, Inc.",1429104600,America/New_York,EDT,-14400000,1.07,7.0,3.0,5.6,6.0,1.7,buy,5,50430000,0.559,-8075000,4543000,1.78,1.981,84567000,29.473,1.088,-0.095319994,-2.02522,-11232000,-422750,-1105000,0.225,0.10191,-0.09549,-0.09694,USD,
6,6310 Nancy Ridge Drive,Suite 101,San Diego,CA,92121,United States,858 752 6170,https://www.cidara.com,Biotechnology,Healthcare,"Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.",73,"{'maxAge': 1, 'name': 'Dr. Leslie  Tari Ph.D.', 'age': 55, 'title': 'Chief Scientific Officer', 'yearBorn': 1967, 'fiscalYear': 2021, 'exercisedValue': 0, 'unexercisedValue': 0}",8,6,8,8,8,1693526400,1672444800,86400,4,1.09,1.08,1.05,1.1092,1.09,1.08,1.05,1.1092,0.0,1.26798,-2.0188682,471224,471224,626772,1166230,1166230,1.07,1.09,1100,1300,96569320,0.46,2.1,1.1419268,0.96746,1.127575,0.0,0.0,USD,50682368,-0.08924,75095770,90251696,1186790,1554275,1690761600,1693440000,0.013099999,0.09252,0.33742002,2.62,0.013300001,0.171,6.25731,1672444800,1703980800,1688083200,-7547000,-0.08,-0.53,-0.05,0.599,-6.276,NCM,EQUITY,CDTX,CDTX,"Cidara Therapeutics, Inc.","Cidara Therapeutics, Inc.",1429104600,America/New_York,EDT,-14400000,1.07,7.0,3.0,5.6,6.0,1.7,buy,5,50430000,0.559,-8075000,4543000,1.78,1.981,84567000,29.473,1.088,-0.095319994,-2.02522,-11232000,-422750,-1105000,0.225,0.10191,-0.09549,-0.09694,USD,
7,6310 Nancy Ridge Drive,Suite 101,San Diego,CA,92121,United States,858 752 6170,https://www.cidara.com,Biotechnology,Healthcare,"Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.",73,"{'maxAge': 1, 'name': 'Ms. Laura A. Navalta', 'title': 'Sr. VP of Clinical Operations', 'exercisedValue': 0, 'unexercisedValue': 0}",8,6,8,8,8,1693526400,1672444800,86400,4,1.09,1.08,1.05,1.1092,1.09,1.08,1.05,1.1092,0.0,1.26798,-2.0188682,471224,471224,626772,1166230,1166230,1.07,1.09,1100,1300,96569320,0.46,2.1,1.1419268,0.96746,1.127575,0.0,0.0,USD,50682368,-0.08924,75095770,90251696,1186790,1554275,1690761600,1693440000,0.013099999,0.09252,0.33742002,2.62,0.013300001,0.171,6.25731,1672444800,1703980800,1688083200,-7547000,-0.08,-0.53,-0.05,0.599,-6.276,NCM,EQUITY,CDTX,CDTX,"Cidara Therapeutics, Inc.","Cidara Therapeutics, Inc.",1429104600,America/New_York,EDT,-14400000,1.07,7.0,3.0,5.6,6.0,1.7,buy,5,50430000,0.559,-8075000,4543000,1.78,1.981,84567000,29.473,1.088,-0.095319994,-2.02522,-11232000,-422750,-1105000,0.225,0.10191,-0.09549,-0.09694,USD,
8,6310 Nancy Ridge Drive,Suite 101,San Diego,CA,92121,United States,858 752 6170,https://www.cidara.com,Biotechnology,Healthcare,"Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.",73,"{'maxAge': 1, 'name': 'Dr. Nicole  Davarpanah J.D., M.D.', 'title': 'Sr. VP of Translational R&D', 'exercisedValue': 0, 'unexercisedValue': 0}",8,6,8,8,8,1693526400,1672444800,86400,4,1.09,1.08,1.05,1.1092,1.09,1.08,1.05,1.1092,0.0,1.26798,-2.0188682,471224,471224,626772,1166230,1166230,1.07,1.09,1100,1300,96569320,0.46,2.1,1.1419268,0.96746,1.127575,0.0,0.0,USD,50682368,-0.08924,75095770,90251696,1186790,1554275,1690761600,1693440000,0.013099999,0.09252,0.33742002,2.62,0.013300001,0.171,6.25731,1672444800,1703980800,1688083200,-7547000,-0.08,-0.53,-0.05,0.599,-6.276,NCM,EQUITY,CDTX,CDTX,"Cidara Therapeutics, Inc.","Cidara Therapeutics, Inc.",1429104600,America/New_York,EDT,-14400000,1.07,7.0,3.0,5.6,6.0,1.7,buy,5,50430000,0.559,-8075000,4543000,1.78,1.981,84567000,29.473,1.088,-0.095319994,-2.02522,-11232000,-422750,-1105000,0.225,0.10191,-0.09549,-0.09694,USD,
